Immuron Limited

IMC

AU000000IMC7

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 07:10:13 28/06/2024 BST			5-day change	1st Jan Change
0.088 ^AUD	0.00%		+10.00%	+14.29%

06-05	Immuron Limited Appoints Jeannette Joughin as Director	CI
05-31	Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director	CI

Immuron Limited Announces Resignation of Richard Jay Berman as Director

October 17, 2019 at 05:11 am

Immuron Limited announced that Mr. Richard Jay Berman has resigned as director of the Company, effective immediately.

Latest news about Immuron Limited

Immuron Limited Appoints Jeannette Joughin as Director	06-05	CI
Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director	05-31	CI
Immuron Limited Announces Stephen Anastasiou Has Resigns as Non-Executive Director	05-02	CI
Immuron Limited Provides Sales Results for the Quarter and Year to Date Ended March 2024	04-10	CI
Immuron's Global Sales Climb 51% in March Quarter; Shares Surge 18%	04-10	MT
Sector Update: Health Care Stocks Gain Late Afternoon	03-07	MT
Sector Update: Health Care	03-07	MT
Top Midday Gainers	03-07	MT
Top Premarket Gainers	03-07	MT
Immuron Moving Anti-Diarrhea Drug to Phase Three Trials	03-07	MT
Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US	03-07	CI
Immuron Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Immuron Limited Reports Unaudited Net Sales Results for the Year to Date Ended January 2024	02-13	CI
Immuron's Travelan Immune Supplement Registers AU$2.7 Million Sales in YTD January	02-13	MT
Immuron Limited Reports Sales Results for First Half 2024	01-16	CI
Immuron Posts Record Travelan Sales in Fiscal H1	01-16	MT
Immuron Limited Clinical Trials Update	12-22	CI
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study	12-04	CI
Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences	18/10/23	CI
Immuron Limited Reports Sales Results for the First Quarter of 2024	11/10/23	CI
Immuron Reports Big Jump in Fiscal Q1 Travelan Sales	11/10/23	MT
Immuron Sees Nearly 8000% Boost in August Sales of Gastrointestinal Drug	14/09/23	MT
Immuron Limited Reports Earnings Results for the Full Year Ended June 30, 2023	29/08/23	CI
Immuron Limited Receives TGA GMP Clearance	09/08/23	CI
Immuron Secures Clearance for Packaging of Immunotherapy Product; Shares Surge 27%	09/08/23	MT

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelerâs diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.

Sector

Pharmaceuticals

Calendar

29/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
IMMURON LIMITED	+14.29%	13.39M
CSL LIMITED	+2.99%	95.18B
SAMSUNG BIOLOGICS CO.,LTD.	-4.34%	37.55B
BIOGEN INC.	-10.41%	33.75B
UCB	+75.79%	28.2B
BIOMARIN PHARMACEUTICAL INC.	-14.61%	15.63B
INCYTE CORPORATION	-3.46%	13.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.31%	11.5B
ALTEOGEN INC.	+184.77%	10.81B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-54.13%	9.23B